SG11202101965QA - Method for selecting neoepitopes - Google Patents

Method for selecting neoepitopes

Info

Publication number
SG11202101965QA
SG11202101965QA SG11202101965QA SG11202101965QA SG11202101965QA SG 11202101965Q A SG11202101965Q A SG 11202101965QA SG 11202101965Q A SG11202101965Q A SG 11202101965QA SG 11202101965Q A SG11202101965Q A SG 11202101965QA SG 11202101965Q A SG11202101965Q A SG 11202101965QA
Authority
SG
Singapore
Prior art keywords
selecting neoepitopes
neoepitopes
selecting
Prior art date
Application number
SG11202101965QA
Other languages
English (en)
Inventor
Monika Sekelja
Karoline Schjetne
Agnete Fredriksen
Original Assignee
Vaccibody As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccibody As filed Critical Vaccibody As
Publication of SG11202101965QA publication Critical patent/SG11202101965QA/en

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/30Detection of binding sites or motifs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Theoretical Computer Science (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
SG11202101965QA 2018-09-27 2019-09-27 Method for selecting neoepitopes SG11202101965QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18197172 2018-09-27
PCT/EP2019/076210 WO2020065023A1 (en) 2018-09-27 2019-09-27 Method for selecting neoepitopes

Publications (1)

Publication Number Publication Date
SG11202101965QA true SG11202101965QA (en) 2021-04-29

Family

ID=63794302

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101965QA SG11202101965QA (en) 2018-09-27 2019-09-27 Method for selecting neoepitopes

Country Status (12)

Country Link
US (1) US12462898B2 (https=)
EP (1) EP3856957A1 (https=)
JP (1) JP7585195B2 (https=)
KR (1) KR102902460B1 (https=)
CN (1) CN112771214B (https=)
AU (1) AU2019346023B2 (https=)
BR (1) BR112021005702A8 (https=)
CA (1) CA3111903A1 (https=)
IL (1) IL281771B2 (https=)
MX (1) MX2021003654A (https=)
SG (1) SG11202101965QA (https=)
WO (1) WO2020065023A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020221783A1 (en) * 2019-04-29 2020-11-05 Vaccibody As Methods for pre-selection of neoepitopes
CN116802738A (zh) * 2020-11-06 2023-09-22 亚马逊科技公司 为个体化癌症疫苗选择新抗原
GB202102606D0 (en) * 2021-02-24 2021-04-07 Univ Oxford Innovation Ltd Treatment of ovarian cancer minimal residual disease
KR20230164118A (ko) 2021-03-26 2023-12-01 니코데 테라퓨틱스 에이에스에이 암 치료를 위한 치료 조합
BR112023023260A2 (pt) 2021-05-10 2024-01-30 Nykode Therapeutics ASA Vetor, métodos para produzir um vetor e para tratar um sujeito tendo uma doença ou uma doença infecciosa, célula hospedeira, e, composição farmacêutica
WO2022238381A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Immunotherapy constructs for treatment of disease
WO2023244997A1 (en) * 2022-06-13 2023-12-21 The University Of North Carolina At Chapel Hill Compositions and methods for inducing anticancer immunity
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
KR102857635B1 (ko) * 2022-11-08 2025-09-10 인바이츠지노믹스 주식회사 면역원성이 높은 유사체를 디자인하는 방법 및 이를 이용한 장치
WO2024100196A1 (en) 2022-11-09 2024-05-16 Nykode Therapeutics ASA Co-expression of constructs and polypeptides
WO2024216073A1 (en) * 2023-04-14 2024-10-17 The Trustees Of Columbia University In The City Of New York Engineered microbes comprising tumor neoantigen vectors for cancer immunotherapy
US20250232833A1 (en) * 2024-01-13 2025-07-17 Noergaard Anders Kaare Cyclin D1 Based Cancer Vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
EP3417874B1 (en) 2012-11-28 2024-09-11 BioNTech SE Individualized vaccines for cancer
EP2983702A2 (en) 2013-04-07 2016-02-17 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
US20160367651A1 (en) 2013-10-01 2016-12-22 Mie University T cell inducing vaccine containing an interepitope sequence that promotes antigen presentation
WO2016015095A1 (en) 2014-07-31 2016-02-04 The University Of Western Australia A method for the identification of immunotherapy-drug combinations using a network approach
WO2016040900A1 (en) 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
US10317402B2 (en) 2014-12-03 2019-06-11 Verik Bio, Inc. Identification, selection and use of high curative potential T cell epitopes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
BR112017022845A2 (pt) * 2015-04-23 2018-07-17 Nantomics, Llc neoepítopos de câncer
EA201792501A1 (ru) * 2015-05-13 2018-10-31 Эйдженус Инк. Вакцины для лечения и профилактики рака
EP3323070B1 (en) * 2015-07-14 2024-05-08 Personal Genome Diagnostics Inc. Neoantigen analysis
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
WO2018136664A1 (en) 2017-01-18 2018-07-26 Ichan School Of Medicine At Mount Sinai Neoantigens and uses thereof for treating cancer
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules

Also Published As

Publication number Publication date
WO2020065023A1 (en) 2020-04-02
MX2021003654A (es) 2021-05-28
JP7585195B2 (ja) 2024-11-18
CA3111903A1 (en) 2020-04-02
CN112771214A (zh) 2021-05-07
BR112021005702A8 (pt) 2022-11-08
AU2019346023A1 (en) 2021-03-25
US20210388438A1 (en) 2021-12-16
IL281771B1 (en) 2025-04-01
KR20210065171A (ko) 2021-06-03
BR112021005702A2 (pt) 2021-06-22
IL281771A (en) 2021-05-31
KR102902460B1 (ko) 2025-12-19
AU2019346023B2 (en) 2024-12-12
EP3856957A1 (en) 2021-08-04
IL281771B2 (en) 2025-08-01
CN112771214B (zh) 2025-06-13
JP2022502416A (ja) 2022-01-11
US12462898B2 (en) 2025-11-04

Similar Documents

Publication Publication Date Title
SG11202101965QA (en) Method for selecting neoepitopes
GB201800298D0 (en) Method
GB201809323D0 (en) Method
GB201807793D0 (en) Method
GB201808554D0 (en) Method
GB201800558D0 (en) Method
GB201811811D0 (en) Method
GB201811813D0 (en) Method
GB201811810D0 (en) Method
GB201805876D0 (en) Method
GB201808663D0 (en) Method
GB201814039D0 (en) Method
GB201803750D0 (en) Method
GB201812603D0 (en) Method
GB201809403D0 (en) Method
GB201804277D0 (en) Method
GB201802744D0 (en) Method
GB201808558D0 (en) Method
GB201807788D0 (en) Method
GB201806240D0 (en) Method
GB201817971D0 (en) Method
GB201817802D0 (en) Method
GB201804289D0 (en) Method
GB201803183D0 (en) Method
GB201802653D0 (en) Method